PMID- 36198548
OWN - NLM
STAT- MEDLINE
DCOM- 20221007
LR  - 20221011
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 63
IP  - 9
DP  - 2022
TI  - [Clinical guidance for the peripartum management of patients with hereditary 
      thrombophilia].
PG  - 1223-1232
LID - 10.11406/rinketsu.63.1223 [doi]
AB  - Hereditary thrombophilia is a condition in which individuals are susceptible to 
      the formation of thrombi due to a hereditary deficiency in the anticoagulant 
      factors antithrombin (AT), protein C, or protein S. The recommendations for 
      peripartum management are as follows: 1) For women with acute venous 
      thromboembolism (VTE) during pregnancy, anticoagulant therapy with a therapeutic 
      dose of unfractionated heparin (UFH) is recommended; 2) For women with a history 
      of VTE, a prophylactic dose of UFH is suggested during pregnancy; 3) For those 
      with AT deficiency, supplementation with an AT preparation in addition to UFH is 
      suggested; 4) For women with no history of VTE, anticoagulant therapy during 
      pregnancy is considered for each thrombophilia type; 5) When anticoagulant 
      therapy consisting of a prophylactic dose of UFH is administered during 
      pregnancy, injection is discontinued with the onset of labor pains in cases of 
      vaginal delivery and 6 hours before the start of delivery in cases of planned 
      delivery or cesarean section; 6) In cases of AT deficiency, regardless of the 
      thrombophilia type, supplementation with AT before and after delivery is 
      suggested; 7) For women with thrombophilia and a history of VTE and for those who 
      receive anticoagulant therapy during pregnancy, postpartum anticoagulant therapy 
      is recommended.
FAU - Kobayashi, Takao
AU  - Kobayashi T
AD  - Hamamatsu Medical Center.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Protein C)
RN  - 9005-49-6 (Heparin)
RN  - Thrombophilia, hereditary
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Antithrombins/therapeutic use
MH  - Cesarean Section
MH  - Female
MH  - *Heparin/therapeutic use
MH  - Humans
MH  - Peripartum Period
MH  - Pregnancy
MH  - Protein C
MH  - Risk Factors
MH  - *Thrombophilia/drug therapy/etiology
OTO - NOTNLM
OT  - Antithrombin deficiency
OT  - Hereditary thrombophilia
OT  - Protein C deficiency
OT  - Protein S deficiency
EDAT- 2022/10/06 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/10/05 21:55
PHST- 2022/10/05 21:55 [entrez]
PHST- 2022/10/06 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
AID - 10.11406/rinketsu.63.1223 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2022;63(9):1223-1232. doi: 10.11406/rinketsu.63.1223.